CytomX Therapeutics (CTMX) Reports revenue

CytomX Therapeutics (NASDAQ: CTMX) reportedrevenue for the quarter came in at $26.6 million versus the consensus estimate of $19.6 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction
• Bernstein sees downside risk to Apple's December quarter results